Jana Small Finance Bank Limited

Financial Services — Banks - Regional · NSE

₹492.00+₹11.65 (+2.43%)

DalalBaazaar Score

58 / 100

🟡 Moderate

Verdict

NEUTRAL

Risk

Low

Driven by small-cap size, which brings sharper price swings.

In simple words: The business is earning a fairly low return on the money invested in it, with both sales and profits growing well. Nothing obvious stands out as stretched — the usual checks on business quality and management still apply.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 6:51 pm

Understanding the Business

Company site ↗

The 60-second version of Jana Small Finance Bank Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Jana Small Finance Bank Limited provides banking and financial services to individuals and enterprises in India. It operates through Treasury, Corporate/Wholesale Banking, Retail Banking, and Other Banking Operations segments.

IndustryBanks - Regional

SectorFinancial Services

Employees26,246

Annual revenue₹3,354 Cr

How does it make money?

Turns over ₹3,354 Cr a year. Of every ₹100 of sales, about ₹10 reaches shareholders as profit. Each of its 26,246 employees supports ₹12.8 lakh of revenue a year, the signature of a people-led business.

Revenue / employee₹12.8 lakh

Who are its competitors?

The closest listed comparisons in its industry are HDFC BANK LTD, ICICI BANK LTD., KOTAK MAHINDRA BANK LTD, AXIS BANK LIMITED. These are the companies its valuation and returns are measured against elsewhere in this report.

Compared side by side in Peers ↓

What is its competitive advantage?Not assessable from these ratios

For a lender, returns on capital are shaped by leverage and funding cost rather than by pricing power, so the usual financial signature of an advantage does not apply. Judge this one on deposit franchise, cost of funds and asset quality — none of which are in this data.

Peer median ROE13.8%

What is the outlook?

3 analysts covering the stock expect revenue to grow about 17.7% and earnings to grow about 4.1% in the year to 2028. These are estimates by people who follow the company, not a forecast for the wider industry.

Est. revenue growth+17.7%

Est. earnings growth+4.1%

Analysts3

What has been driving growth?

Growth has come mainly from selling more, rather than from keeping more of each sale. Over 3 years revenue moved +51% while net margin moved -16% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect+51%

Margin effect-16%

DalalBaazaar Score

58/ 100

Moderate

Weighted across six categories. Every point is explained below.

✗ ROE of 7.3% is weak
✗ ROE has fallen by 6.9 points over the period

Quality vs. Valuation

Company Quality

58/ 100

Average

How good the business is, ignoring the share price entirely.

Valuation

53/ 100

Fair

What you are being asked to pay, ignoring how good the business is.

A reasonable business at a reasonable price — neither the quality nor the valuation stands out in either direction.

Historical Valuation

Current P/E

13.7x

3Y Median

9.6x

34 monthly readings · mean 11.1x · range 4.4x–27.3x

Sector Median

17.0x

median of 4 sector peers

⚠️Current valuation is approximately 42% above its 3y median of 9.6x. Paying more than usual needs a reason — faster growth, a better balance sheet, or a re-rating you believe in.

🟢Against its sector it trades 19% below the peer median of 17.0x.

vs. its own history

Expensive

9.6x median over 34 months · +42%

vs. sector peers

Fair

17.0x median of 4 peers · -19%

vs. generic bands

Cheap

Below 15x

EV/EBITDA

—

PEG

1.62

What's Good / What's Bad

🟢 What's Going Well1

Consistently profitable
Profitable in every one of the last 4 reported years.

🔴 What Needs Attention1

Return on equity is falling
ROE has dropped from 14.2% to 7.3% — each rupee of shareholder capital earns less than it did.

Red Flags

No automated checks triggered

None of the automated financial checks below were triggered on the years of data available. That is not the same as a clean bill of health — see what could not be checked.

Investment Thesis

🟢 Bull CaseWhat could make this work?

Earnings have proved durable
Profitable in every one of the last 4 reported years. Consistency lowers the risk that any single bad year is structural rather than cyclical.

🔴 Bear CaseWhat could go wrong?

The price already assumes success
The stock trades 42% above its own median multiple. At this level the business has to deliver just to stand still, and a stumble is repriced twice — lower earnings on a lower multiple.
Returns on shareholder capital are falling
ROE has dropped from 14.2% to 7.3%. Each rupee of equity earns less than it did, so profit growth increasingly depends on raising more capital rather than on the existing base working harder.
Earnings are hard to forecast
Profit has swung sharply from year to year, so any single year — good or bad — is a weak guide to the next. Cyclical earnings deserve lower multiples for that reason.
Size brings its own risk
Small Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1Revenue growth stays above 11% a year✓ 14.8% CAGR
Latest reported year was 25.1%. The bar is set below the established compounding rate, so ordinary variation does not trip it.
2Return on equity stays above 8%✗ 7.3%
For a lender this is the cleanest single read on whether the book is being grown profitably.
3Valuation vs its own median of 9.6x✗ 13.7x today
A re-rating above its own history needs a reason; without one it is just a higher price.

Investment Checklist

7 / 10 checks passed

✗ Strong return on equity (ROE ≥ 15%)
✓ Healthy net margin (≥ 10%)
✓ Generates positive free cash flow
✗ Manageable leverage (Debt/Equity < 1.0)
✓ Revenue growing year-over-year
✓ Profit growing year-over-year
✓ Not trading at an extreme valuation (P/E < 40x)
✓ Not buying right at the 52-week high
✓ Analyst consensus isn't majority-sell
✗ Short-term technical trend isn't bearish

Price history

Quick Metrics

6 good · 4 neutral · 1 weak

Market Cap

₹5,206 Cr

Small Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

13.7x

Cheap

Cheap against the generic band

P/B Ratio

1.16x

Reasonable

Reasonable against the company's book value

EPS (TTM)

₹35.93

Profitable

Profitable on a per-share basis

ROE

7.3%

Weak

Weak capital efficiency

ROCE

Not meaningful

N/A for lenders

Banks and NBFCs don't report capital employed the way other businesses do

Debt/Equity

1.02x

Moderate

Moderate leverage

Revenue Growth (YoY)

25.1%

Healthy

Healthy top-line growth

Profit Growth (YoY)

52.2%

Healthy

Profits growing at a healthy clip

Dividend Yield

None

No dividend yield reported — usually means no payout, but verify if one was recently initiated

Free Cash Flow

₹471 Cr

Cash generative

Generates cash even after funding its capex

More Metrics

P/E (Forward)

7.2x

Improving

Below the trailing multiple — the street expects earnings to grow into the price

Operating Margin

18.7%

Good

Healthy core-business profitability

Net Margin

12.9%

Good

Strong bottom-line conversion

Beta (vs Nifty)

0.56

Defensive

Steadier than the market

52W Range Position

58%

Mid-range

Technical Snapshot

SMA 20 / SMA 50

505.4 / 528.5

Bearish alignment (short < long)

Price vs SMA 200

Above

Long-term uptrend

RSI (14)

35.4

Neutral momentum

Financial Trend (4-Year)

Metric	FY23	FY24	FY25	FY26	3Y CAGR
Revenue	₹2,215 Cr	₹2,625 Cr	₹3,011 Cr	₹3,354 Cr	+14.8%
PAT (Net Profit)	₹256 Cr	₹670 Cr	₹501 Cr	₹326 Cr	+8.4%
EPS	₹24.47	₹90.72	₹47.67	₹30.92	+8.1%
ROE	14.2%	18.7%	12.2%	7.3%	—
Total Debt	₹5,477 Cr	₹4,411 Cr	₹3,377 Cr	₹4,547 Cr	-6.0%
Free Cash Flow	-₹1,163 Cr	₹631 Cr	₹4,000 Cr	₹471 Cr	—

🟢 Revenue has grown at 14.8% a year over 3 years.

🟢 PAT (Net Profit) has grown at 8.4% a year over 3 years.

🟢 EPS has grown at 8.1% a year over 3 years.

🔴 ROE has fallen from 14.2% to 7.3% over 3 years (-6.9 pts).

🟢 Total Debt has shrunk at 6.0% a year over 3 years.

🟢 Free Cash Flow has turned positive, from -₹1,163 Cr to ₹471 Cr.

Balance Sheet & Cash Flow — FY2026

Total Assets

₹47,448 Cr

Total Liabilities

₹42,978 Cr

Cash & Equivalents

₹2,550 Cr

Operating Cash Flow

₹594 Cr

Capex

-₹122 Cr

Shareholding (proxy)

Institutional Holding

16.8%

Insider Holding

47.4%

Analyst Consensus

Recommendations

3 Buy · 0 Hold · 0 Sell

Target Price (Mean)

₹598.33

+21.6% vs CMP

Target Range

₹590 – ₹605

Peer Comparison

Company	P/E	ROE
HDFC BANK LTD	15.9x	13.8%
ICICI BANK LTD.	18.1x	16.5%
KOTAK MAHINDRA BANK LTD	21.9x	11.2%
AXIS BANK LIMITED	14.5x	13.4%

Recent News

2 mixed4 general

Federal Bank–Jana Small Finance Bank in advanced talks for a share swap deal

Moneycontrol.com, 25 Sept

Jana Small Finance Bank Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast

Univest, 13 AugAnalyst view

🟡Mixed / dependsBroker commentary — an opinion about the price rather than new information about the business.

Jana Small Finance Bank (JSFB.NS) Jumps 3.53% to ₹499.45 as Buyers Reclaim Mid-Range Levels - Money Flow Index

siam.in, 05 Oct

Federal Bank-Jana SFB Deal CONFIRMED? Banks' Shares PLUNGE Amid Acquisition Rumors!

MarketSmith India, 25 AugM&A

🟡Mixed / dependsAcquisitions change the balance sheet before they change the earnings. Look at what was paid, how it was funded, and whether debt rose.

Jana Small Finance Bank (NSEI:JSFB) Stock Price

Simply Wall Street, 29 Jul

Small-, mid-cap banks shine: Jana Small, South Indian Bank surge up to 7%

Business Standard, 21 Jul

Watch Items

This is a financial-sector business: borrowing is its raw material, not leverage in the usual sense. Debt/Equity and ROCE here aren't comparable to a manufacturer's — read them alongside NIM, GNPA and capital adequacy from the company's own disclosures.
Cross-check against the company's latest quarterly filing / investor presentation before acting.

DalalBaazaar Thesis

StrongBusiness Quality · Valuation

MiddlingFinancial Health · Growth · Profitability · Risk

Points for each in the Score ↑

Unremarkable in both directions

A reasonable business at a reasonable price. Nothing here is alarming and nothing is compelling, which usually means the decision rests on things this data cannot see — the industry's direction, management's intent, and what else is available to you.

2 of 3 tripwires tripped — Return on equity stays above 8%; Valuation vs its own median of 9.6x · see Key things to watch ↑